Novo Nordisk H1 2026 Earnings: DKK 175.3B Sales, DKK 69.5B Net Profit, Outlook 'Raised' to 0% to −6%

On 4 August 2026, Novo Nordisk reported Q2 sales of DKK 78.5 billion (+3% at constant exchange rates) and adjusted operating profit of DKK 33.4 billion (+11% at CER), then "raised" full-year guidance to 0% to −6% growth for both adjusted sales and adjusted operating profit. The six-month reported P&L still looks like a growth company — H1 net sales DKK 175.3 billion, net profit DKK 69.5 billion — but the adjusted lens and the outlook range say the GLP-1 franchise is past peak growth.

The Headline Numbers​

All figures below are in DKK millions from Novo Nordisk's financial report for 1 January–30 June 2026 (company announcement No 48 / 2026; also furnished to the SEC as a Form 6-K). The headline table matches the six-month fence; Q2 is the three-month slice used in management's growth narrative (stated in prose). No silent USD conversion.

Q2 2026 (three months, for context only): net sales DKK 78,488M (+3% CER); reported operating profit DKK 27,061M (−16% CER); adjusted operating profit DKK 33,389M (+11% CER); net income DKK 20,989M.

Two reconciliations matter more than any single percentage.

First, H1 reported sales (+18% CER) versus H1 adjusted sales (+2% CER). Adjusted growth strips the non-recurring impact of US 340B Drug Pricing Program rebate provision reversals. In plain language: a large chunk of the six-month sales growth is the absence of last year's provision noise, not a permanent acceleration in underlying GLP-1 volume.

Second, Q2 reported operating profit (−16% CER) versus adjusted operating profit (+11% CER). Reported EBIT was hit by (a) the year-ago 340B reversal that inflated Q2 2025 and (b) DKK 6.3 billion of non-cash impairment charges in Q2 2026 on intangible pipeline assets, including monlunabant (DKK 4.0 billion). Adjusted EBIT removes that impairment stack. The ledger fence below uses the reported six-month income statement — the one that must zero-sum — so impairments and other operating items stay inside the P&L you can audit.

Revenue Deep Dive​

H1 segment sales (DKK million):

Obesity and Diabetes care is still ~94% of sales. Segment operating profit for that franchise was DKK 86,356 million in H1 (52.4% margin) versus DKK 71,178 million a year earlier (49.0%). Rare disease contributed DKK 323 million of segment operating profit (3.1% margin) after a Q2 operating loss.

Commercial color from the release is about product mix and geography, not scarcity theater:

• Wegovy® pill weekly US prescriptions exceeded 265,000 in the week ending 17 July; the franchise remains the market leader among branded obesity medications by new patient starts.
• Total US Wegovy® weekly TRx around 575,000; more than 5 million TRx since the pill launch.
• Wegovy® HD launched in the US in April; 7.2 mg single-dose pen launched in the UK in June; pill launches in the UAE (June) and UK (July).
• Adjusted Obesity care sales growth of 19% at CER in the highlights.
• Medical treatment provided to 41.6 million people with diabetes and 4.9 million with obesity.

Management signal scan​

Before writing, we scanned the release for the seven demand/supply themes this series tracks (demand exceeding supply, industry upcycle, market expansion ahead of plan, product ramps beating expectations, rising selling prices, tight supply, robust demand). Those themes are largely absent. The company does not say it is sold out, supply-constrained, or unable to meet demand. It does not claim an industry upcycle or sustained ASP increases. What it does say is narrower and more defensive: GLP-1 volume growth, "favourable US rebate adjustments," "encouraging early uptake" of the pill outside the US, and an outlook that is "raised" into a band that still tops out below zero. Absence is the finding — this is no longer a scarcity narrative; it is a volume-plus-pricing-pressure narrative.

Pipeline news in the same release is mixed: EMA approvals for Wegovy® HD and the pill, but the ZEUS phase 3 trial with ziltivekimab did not meet the primary endpoint.

The Margin Story​

Reported H1 gross profit was DKK 144,613 million on sales of 175,311 — an implied gross margin of 82.5%, down from 83.4% in H1 2025 (gross profit 129,208 on sales 154,944). Cost of goods sold rose to DKK 30,698 million from 25,736.

Operating expense mix (H1 2026, DKK million):

SG&A in the ledger is sales and distribution plus administrative (29,523). R&D is the standout: up to DKK 28.1 billion from 22.0 billion. Sales and distribution actually fell year over year in the six-month window — unusual for a launch cycle, and consistent with a company that is no longer spending as if every vial is scarce.

The adjusted-versus-reported gap is the margin story investors will argue about. H1 adjusted operating profit of DKK 66,247 million is below reported operating profit of 86,679, because the 340B provision reversals that inflate reported sales/EBIT are excluded from the adjusted view. Q2 flips the other way: adjusted EBIT (33,389) is above reported (27,061) because the DKK 6.3 billion impairments are excluded. Same company, same half-year — two different operating-profit identities depending on which non-recurring items you keep.

Full-year 2026 outlook (CER), per the 4 August outlook release: adjusted sales growth 0% to −6%; adjusted operating profit growth 0% to −6%. Management calls this an improvement driven by "increased expectations for GLP-1 product sales." A raise into a range that still allows a mid-single-digit decline is the clearest signal that pricing and competitive pressure are inside the guidance, not a footnote.

The One Big Question: Can Volume Offset Pricing?​

Novo Nordisk's own framing answers the question it wants asked: Wegovy® pill adoption and International Operations launches will drive volume. The question the numbers force is harder: can volume growth outrun net price compression and one-off noise long enough to keep adjusted growth near the top of a 0% to −6% band?

Evidence on the volume side: pill TRx, HD launch, ~60-country Wegovy® footprint, 19% CER adjusted obesity-care sales growth in the highlights. Evidence on the price/noise side: the entire adjusted-sales bridge, the 340B provision history, and Q2 reported sales growth of only 3% CER. The balance sheet adds a third thread — sales deductions and product returns of DKK 140,201 million in current liabilities at 30 June 2026 (versus 133,349 at year-end 2025). That liability is where US rebate mechanics live; it is not a footnote.

Cash rose to DKK 44,482 million from 26,464 at year-end. Borrowings (current + non-current) totaled DKK 140,127 million. Property, plant and equipment reached DKK 231,758 million — the manufacturing footprint behind the volume thesis — while intangible assets fell to 102,167 (impairments visible in the P&L).

Tracking a DKK 175B Half-Year in Plain Text​

Modeling Novo Nordisk in Beancount forces every million kroner of net profit to reconcile. The house chart (how we model every company) uses MDKK (DKK millions). Income postings are credits (negative); expenses are debits (positive); Equity:Adjustments absorbs net income so the transaction sums to zero.

The fence below is the six-month H1 2026 reported income statement dated 2026-06-30 — not the Q2-only slice:

; H1 2026 Income Statement — six months ended June 30, 2026
; Check: -175311 + 30698 + 28071 + 29523 + 340 - 2368 + 19501 + 69546 = 0 ✓
 
2026-06-30 * "Novo Nordisk A/S" "FY2026H1 Income Statement"
  Income:Revenue                         -175311 MDKK
  Expenses:CostOfRevenue                   30698 MDKK
  Expenses:ResearchAndDevelopment          28071 MDKK
  Expenses:SellingGeneralAdministrative    29523 MDKK  ; sales and distribution 27,074 + administrative 2,449
  Expenses:OtherNet                          340 MDKK  ; other operating income and expenses
  Income:OtherNet                          -2368 MDKK  ; financial items net (gain)
  Expenses:IncomeTax                       19501 MDKK
  Equity:Adjustments                       69546 MDKK  ; net income offset (RE set by balance assertion)

The balance-sheet number that carries the commercial story is not cash — it is the DKK 140.2 billion sales-deductions liability sitting in Liabilities:Current:Other, next to trade payables of only DKK 14.6 billion. In a rebate-heavy US GLP-1 business, the gross-to-net machinery is larger than accounts payable.

Browse the full FY2022–FY2026 H1 ledger:

The Multi-Year Arc​

Reported annuals (DKK million) from Novo Nordisk's FY2022–FY2025 financial reports, plus H1 2026:

Sales nearly doubled from FY2022 to FY2025. Operating margin peaked in the mid-40s and compressed in FY2025 when sales growth slowed to 6% reported / 10% CER and restructuring plus Catalent-related costs hit EBIT. H1 2026's 49.4% reported operating margin looks strong — until you remember the adjusted operating profit is DKK 66.2 billion, not 86.7 billion, and full-year guidance allows adjusted EBIT to fall.

PPE tells the capacity story underneath: DKK 66.7 billion (2022) → 91.0 (2023) → 162.5 (2024) → 208.4 (2025) → 231.8 at mid-2026. The company built for a scarcity world; H1 2026 is the first clear half where the P&L language is about volume and price, not inability to supply.

The Verdict: Bull vs. Bear​

Bull Case

• Wegovy® pill TRx and HD launch keep US new-patient share; International Operations launches compound into 2027.
• H1 R&D of DKK 28.1 billion funds the next wave (oral and higher-dose injectables already in approval/launch).
• Reported H1 net profit of DKK 69.5 billion and cash of DKK 44.5 billion fund dividends and buybacks while the franchise digests competition.
• A "raised" outlook that still centers near flat may prove conservative if volume beats the low end of −6%.
• Gross margin still above 80% leaves room to trade price for volume without breaking the model.

Bear Case

• Adjusted H1 sales growth of only 2% CER is the cleaner read of the run-rate; reported +18% is not the baseline.
• Full-year guidance of 0% to −6% embeds pricing pressure management is no longer papering over with scarcity language.
• Q2 impairments (DKK 6.3 billion) and the ZEUS miss show pipeline optionality is not one-directional.
• Sales-deduction liabilities above DKK 140 billion keep gross-to-net opaque and volatile quarter to quarter.
• The seven classic "demand exceeds supply" signals are gone — competition and channel dynamics, not capacity, set the ceiling.

Our Take. Novo Nordisk is still an extraordinary cash compounder, but H1 2026 is the half where the storyboard changed. The auditable six-month ledger shows DKK 175.3 billion of sales and DKK 69.5 billion of net profit; the adjusted bridge and the 0% to −6% outlook show a franchise managing price and competition rather than rationing supply. Own it for the volume option on oral Wegovy® and the manufacturing asset base — not for a return to mid-30% CER sales growth.